Mesa Biotech’s Rapid Test For COVID-19 Gets Emergency FDA Approval
The Food and Drug Administration (FDA), U.S. is using its Emergency Use Authorization (EUA) powers to increase the pool of available COVID-19 testing resources in the UNITED STATE, and also now you can include another fast test to the list that gives the result in just 30 minutes. Mesa’s test can be used in the frontline of care including in healthcare facilities, hospitals, and clinics, with multiple parallel tests to be run due to its small size.
One of the rapid tests by Cepheid was approved on Monday and Mesa’s Biotech’s rapid test complies with one by Cepheid. Both the tests identify the viral DNA in the mucous sample of the patients and are PCR-based molecular tests. Since both these test offer lab-quality results, these tests can stop a crucial expansion of the technologies offered to those looking to compact the spread of the novel the COVID-19, however, they can do a lot faster and also without the need of transportation of the samples from the point of collection to the testing centers.
The Mesa’s Accula COVID-19 test uses the throat and nasal swab samples to detect COVID-19.
On-site testing has advantages including limiting the potential exposure of medical workers to the infection, accessibility and rapid results. While testing on-site, the worry of more people getting exposed to the virus in the chain can be avoided, including logistics, delivery people, lab technicians, and individuals who carry out the diagnosis.
These tests will need the facilities that are furnished with Mesa’s Accula testing system, yet its equipment is already in operation for testing flu, and other much less serious equipment, and also it was originally made particularly to attend to use on the frontlines to combat worldwide pandemics, consisting of SARS before the present COVID-19 pandemic.
Author: Sruthi S
